PTHS · AMEX
Pelthos Therapeutics (PTHS) Stock Price & Fundamentals
Pelthos Therapeutics (PTHS) closed at $784.76 on Oct 9, 2026, down 0.29% from the previous close of $787.05.
Share price, past year
1Y +26.85%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $784.76 |
| Sep 30, 2026 | $770.45 |
| Aug 31, 2026 | $770.46 |
| Jul 31, 2026 | $760.62 |
| Jun 30, 2026 | $758.91 |
| May 29, 2026 | $788.89 |
| Apr 30, 2026 | $746.68 |
| Mar 31, 2026 | $754.15 |
| Feb 27, 2026 | $729.82 |
| Jan 30, 2026 | $701.92 |
| Dec 31, 2025 | $677.76 |
| Nov 28, 2025 | $652.74 |
| Oct 31, 2025 | $640.68 |
Key statistics
- Market cap
- $2.92B
- P/E (TTM)
- —
- EPS (TTM)
- −$28.73
- Revenue (TTM)
- $43.30M
- Net income (TTM)
- −$86.39M
- Shares outstanding
- 3.7M
- Dividend yield
- —
- 52-week range
- $599.85 – $808.14
Pelthos Therapeutics's market cap is $2.92B, based on a share price of $784.76 and 3.7M shares outstanding as of Jun 30, 2026.
Financials
Pelthos Therapeutics reported revenue of $16.80M for fiscal 2025.
Pelthos Therapeutics reported a net loss of $43.32M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $16.80M | — | −$43.32M | −257.9% | −$23.04 | −$22.69M |
| FY2024ended Dec 31, 2024 | $0.00 | — | −$7.96M | — | −$14.27 | −$5.79M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $15.60M | −$23.42M | −$6.62 |
| Q1 FY2026ended Mar 31, 2026 | $10.91M | −$25.07M | −$7.57 |
| Q4 FY2025ended Dec 31, 2025 | $9.39M | −$21.66M | −$9.24 |
| Q3 FY2025ended Sep 30, 2025 | $7.41M | −$16.24M | −$5.30 |
| Q2 FY2025ended Jun 30, 2025 | $0.00 | −$3.45M | −$5.29 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$1.97M | −$3.21 |
Company profile
- Name
- Pelthos Therapeutics Inc.
- Ticker
- PTHS
- Exchange
- AMEX
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 4020 Stirrup Creek Drive, Suite 110, Durham, NC 27703
- Incorporated in
- NV
- Fiscal year ends
- December
- SEC CIK
- 0001919246
Recent SEC filings
- Oct 1, 2026
- Aug 13, 2026
- Aug 13, 2026
- Aug 13, 2026
- Aug 13, 2026
- May 28, 2026
- May 21, 2026
- May 14, 2026
Frequently asked questions
What is Pelthos Therapeutics's stock price?
Pelthos Therapeutics (PTHS) closed at $784.76 on Oct 9, 2026, down 0.29% from the previous close of $787.05.
What is Pelthos Therapeutics's market cap?
Pelthos Therapeutics's market cap is $2.92B, based on a share price of $784.76 and 3.7M shares outstanding as of Jun 30, 2026.
How much revenue does Pelthos Therapeutics make?
Pelthos Therapeutics reported revenue of $16.80M for fiscal 2025.
Does Pelthos Therapeutics pay a dividend?
Pelthos Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Pelthos Therapeutics Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures